NCT07095907 Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment
| NCT ID | NCT07095907 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Asociación para Evitar la Ceguera en México |
| Condition | Epiretinal Membrane Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2025-06-10 |
| Primary Completion | 2025-12-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2025-06-10 with a primary completion date of 2025-12-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate postsurgical functional changes in patients with advanced epiretinal membrane (ERM) (stages 3 and 4) by integrating a controlled macular detachment with a balanced salt solution to the conventional ERM peeling technique.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years of age. * Patients with a confirmed diagnosis of ERM grade III or IV by Optical Coherence Tomography who present visual disturbances such as metamorphopsia or visual impairment (measured in letters on the ETDRS scale) but who do not reflect end-stage visual impairment. * Patients suitable for vitreoretinal surgical procedures, with no uncontrolled medical comorbidities that contraindicate surgery. * Patients who understand the objectives and risks of the study and sign an informed consent form. Exclusion Criteria: * Patients with a confirmed diagnosis of grade III or IV ERM by Optical Coherence Tomography who do not have the ability to improve their visual acuity. * Patients diagnosed with ocular pathologies that significantly affect their visual acuity, such as moderate or advanced glaucoma, non-glaucomatous optic neuropathies, or optic media opacities such as leukomas, significant corneal edema, or other maculopathies such as macular atrophy or macular ischemia.
Contact & Investigator
Raul Velez, MD
PRINCIPAL INVESTIGATOR
Asociación para Evitar la Ceguera en México
Frequently Asked Questions
Who can join the NCT07095907 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epiretinal Membrane Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07095907 currently recruiting?
Yes, NCT07095907 is actively recruiting participants. Contact the research team at rvelezmx@yahoo.com for enrollment information.
Where is the NCT07095907 trial being conducted?
This trial is being conducted at Mexico City, Mexico.
Who is sponsoring the NCT07095907 clinical trial?
NCT07095907 is sponsored by Asociación para Evitar la Ceguera en México. The principal investigator is Raul Velez, MD at Asociación para Evitar la Ceguera en México. The trial plans to enroll 36 participants.